

CELLULAR THERAPY: A NEW FRONTIER IN THE FIGHT AGAINST CANCER

ohcare.com
start here



Chimeric antigen receptor T-cell therapy (CAR-T) is one of the most exciting cancer treatment breakthroughs in recent years, and OHC is the first, most experienced, and only certified independent adult cancer group in the region to bring CAR-T for adults with aggressive blood cancers, ushering in a new frontier in the fight against cancer.

CAR-T has shown dramatic results, giving a new sense of hope to many patients previously considered terminal. Now in remission, many are enjoying a good quality of life.

CAR-T is a type of immunotherapy that retrains the body's immune system to fight cancer. It uses genetically engineered immune T-cells to recognize specific proteins on tumor cells.


- Thousands of T-cells are extracted from the patient or a healthy donor and reengineered in a lab to produce special receptors that fight and kill cancer cells.
- The cells are infused into the patient.
- These cells continue to multiply in the patient's body. They recognize and kill cancer cells.
- If the cancer returns, the T-cells may attack again and kill the returning cancer.
- OHC's cancer research and clinical trials program is at the forefront evaluating allogeneic therapies that use T-cells from healthy donors. OHC was among the first in the world to evaluate an allogeneic therapy for B-cell non-Hodgkin lymphoma. OHC cancer experts are expanding this treatment to other B-cell malignancies and solid tumors.

New Clinical Trials: OHC continues to evaluate cellular therapy through its nationally-recognized clinical trials program.




To refer a patient or to learn more about CAR-T, **please call 1-888-649-4800** or visit **ohcare.com**.


OHC offers CAR-T at its Kenwood office, 4777 E. Galbraith Road, Suite 300, Cincinnati, Ohio 45236, in collaboration with The Jewish Hospital-Mercy Health Cincinnati Cancer and Cellular Therapy Center (CCCTC).



James H. Essell, MD
OHC Hematologist/Oncologist,
Cellular Therapy
Medical Director of the CCCTC
and Chair, Cellular Therapy,
US Oncology



E. Randolph Broun, MD
OHC Hematologist/Oncologist,
Cellular Therapy
Associate Director
of the CCCTC



Miguel Islas-Ohlmayer, MD
OHC Hematologist,
Cellular Therapy
Associate Director
of the CCCTC



Kruti Patel, DO
OHC Hematologist/Oncologist,
Cellular Therapy
Associate Director
of the CCCTC